Spots Global Cancer Trial Database for follicular lymphoma grade 3b
Every month we try and update this database with for follicular lymphoma grade 3b cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma | NCT05412290 | B Cell Lymphoma Aggressive Lymp... Diffuse Large B... High-grade B-ce... Transformed Lym... Follicular Lymp... | Mosunetuzumab | 18 Years - | Washington University School of Medicine | |
| Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma | NCT05412290 | B Cell Lymphoma Aggressive Lymp... Diffuse Large B... High-grade B-ce... Transformed Lym... Follicular Lymp... | Mosunetuzumab | 18 Years - | Washington University School of Medicine | |
| Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma | NCT05464329 | Diffuse Large B... High-grade B-ce... Transformed B-C... Follicular Lymp... | Mosunetuzumab DHAX ICE | 18 Years - | Washington University School of Medicine | |
| Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | NCT05326243 | Diffuse Large B... Primary Mediast... Large B-cell Ly... Follicular Lymp... Follicular Lymp... | CD19-targeted c... | 14 Years - 70 Years | Pell Bio-Med Technology Co., Ltd. | |
| Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | NCT05326243 | Diffuse Large B... Primary Mediast... Large B-cell Ly... Follicular Lymp... Follicular Lymp... | CD19-targeted c... | 14 Years - 70 Years | Pell Bio-Med Technology Co., Ltd. | |
| Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma | NCT05464329 | Diffuse Large B... High-grade B-ce... Transformed B-C... Follicular Lymp... | Mosunetuzumab DHAX ICE | 18 Years - | Washington University School of Medicine | |
| Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL | NCT06093841 | Lymphoma, Large... Follicular Lymp... High-grade B-ce... Mediastinal B-C... | Relmacabtagene ... Fludarabine Cyclophosphamid... | 18 Years - | Shanghai Ming Ju Biotechnology Co., Ltd. | |
| Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy | NCT05377307 | Diffuse Large B... Large B-cell Ly... Primary Mediast... Follicular Lymp... Follicular Lymp... | Pell's lentivir... | - | Pell Bio-Med Technology Co., Ltd. | |
| Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies | NCT04088890 | B-ALL B-cell Non Hodg... DLBCL Follicular Lymp... | Fludarabine Cyclophosphamid... CD22 CAR | 18 Years - | Stanford University | |
| Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies | NCT04088890 | B-ALL B-cell Non Hodg... DLBCL Follicular Lymp... | Fludarabine Cyclophosphamid... CD22 CAR | 18 Years - | Stanford University | |
| Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma | NCT03570892 | Non-Hodgkin Lym... | Tisagenlecleuce... Platinum-based ... | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
